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Using an RNA/peptide dual-aptamer probe, both PSMA (+)
and PSMA () prostate cancer cells were simultaneously
detected by electrochemical impedance spectroscopy. This
approach can be applied as a general tool for early diagnosis
of prostate cancer.
Early diagnosis of prostate cancer has been a matter of great
concern as its occurrence has increased.1 A prostate biopsy
test, a microscopic examining process, is one of the key
diagnosis tools for prostate cancer,2 yet this method is not
used for all suspected cases because it would result in many
unnecessary biopsies as well as acute pain for patients and a
large social cost. Several tests such as a digital rectal examina-
tion (DRE), a blood test for prostate specific antigen (PSA),
and transrectal ultrasonography (TRUS) are generally con-
ducted prior to the biopsy test for the initial diagnosis.3
However, such initial tests provide relatively high erroneous
results due to their indirect processes.4 Thus, it is necessary to
investigate a new direct preliminary testing method which can
provide more correct and sensitive results.
Prostate cancer has two types of cell lines, PSMA (+) and
PSMA () cells, based on the expression of the prostate
specific membrane antigen (PSMA, a prostate cancer marker
protein).5 Studies on PSMA (+) prostate cancer6 have been
accelerated in diagnosis and drug targeting after its specific
anti-PSMARNA aptamer (A10) was identified.7 However, the
late discovery of PSMA () specific ligand, DUP-1 peptide
aptamer, has limited the investigation of diagnosis and drug
targeting for the PSMA () cells.8 Furthermore, the simul-
taneous detection of both cell types has not been reported yet.
Based on this need to develop new techniques for both types of
prostate cancer including the PSMA () cell line, we have
designed a dual-aptamer probe, conjugating A10 RNA aptamer
to DUP-1 peptide aptamer, for a direct electrochemical
impedance spectroscopy (EIS) sensor.
Electrochemical detection methods can offer a sensitive,
selective, economical, and miniaturized device for biological
applications.9 Of the various electrochemical methods, EIS
analysis allows for detection of capacitance, reactance and
resistance changes originating from surface species.10 Thus,
this EIS method is highly suitable for measuring the surface
appearance of an electrode.
Aptamer-based detection methods are attractive because of
their high sensitivity and selectivity to the target molecule, and
their good stability in various physical and chemical environ-
ments. In this study, two aptamers specific to prostate cancer
cells, an anti-PSMA RNA aptamer7 (A10,GGGAGGAC-
GAUGCGGAUCAGCCAUGUUUACGUCACUCCUUG-
UCAAUCCUCAUCGGC, underlined nucleotide represents
the modified pyrimidines of 20-F UTP and 20-F CTP) for
the PSMA (+) cell line and a DUP-1 peptide aptamer8
(FRPNRAQDYNTN) for the PSMA () cell line, were con-
jugated to streptavidin to build the dual-aptamer probe. Prior
to the EIS measurement, the specificity of aptamers to prostate
cancer cells was confirmed by a cell labeling experiment with
streptavidin modified Q655 dots (Fig. S1w). Dual-aptamer
modified Q655 dots were bound to both PSMA (+) cell,
LNCaP cell lines, and PSMA () cell, PC3 cell lines, but not
to non-related HeLa cells. A small amount of the Q655 was
bound to PNT2 cells, a prostate normal cell line, and this
reflects weak expression of PSMA.11 The labeling experiments
clearly show that the dual-aptamer probe could then be
generally targeted to both LNCaP and PC3 cells.
As presented in Fig. 1, both biotin-modified A10 and
DUP-1 aptamers combine with streptavidin to form the dual-
aptamer probe on the surface of the Au working electrode
(details in the electronic supplementary informationw). When
prostate cancer cells were applied into sample solution, impedance
would be increased by difficulty of charge transfer through
physical blocking by bound cells to the aptamer probe on the
electrode surface.
Fig. 1 Schematic illustration for detection of prostate cancer cells.
The modification of the Au electrode surface has been performed in
the following sequence: (a) biotin-thiol + spacer, (b) streptavidin
(SA), (c) A10 + DUP-1, (d) BSA, and (e) prostate cancer cells.
Inhibition of the charge transfer was maximized by binding of prostate
cancer cells to its specific aptamers on the surface of the electrode.
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The surface decoration of the working electrode was per-
formed in several steps. At first, the primary modification of
biotin on the working electrode was carried out using 0.1 mM
biotinylated thiol (HSCH2(CH2)9CH2NH2CO-biotin) with
50 mM spacer, 6-mercapto-1-hexanol (HSCH2(CH2)4CH2OH)
by immersion in 200 mL ethanol–chloroform (50/50) solution
with shaking for 14 h at RT.12 Secondly, 200 mL of
0.1 mg mL1 streptavidin with 50 mg mL1 BSA were applied
to the primary modified working electrode in 200 mL PBS
(pH 7.4) for 30 min, and then various ratios of biotinylated A10
aptamer (10–15 mM) and DUP-1 aptamer (10–20 mM) were
applied. Finally, BSA (0.2 mg mL1) was added to the
electrode for 30 min to prevent the non-specific interactions
for effective sensing. Prostate cancer cells could then be
selectively bound to the aptamer probe. Using EIS analysis,
these steps can be readily detected by analyzing the change in
charge transfer resistance (Rct) identified from the diameter of
the semicircle in the Nyquist plots, which describe the resistance
for transferring the electrons of the [Fe(CN)6]
3/4 ions (Fig. 2).
When both A10 and DUP-1 aptamers are conjugated through
streptavidin, it is clear that the ratio of the two aptamers is critical
for impartial targeting. Thus, various ratios (A10 :DUP-1) of
1.5 : 1, 1 : 1, 1 : 1.5, and 1 : 2 were tested. The critical A10 :DUP-1
ratio of 1 : 2 was found to successfully target both types of
prostate cancer cells by EIS measurements (Fig. S2w).
Five cancer cell lines including prostate cancer cells were
prepared for the controlled experiments: LNCaP from PSMA
(+) prostate cancer, PC3 from PSMA () prostate cancer,
HeLa from cervical cancer, SW620 from colon cancer, and
MCF-7 from breast cancer. Additionally, PNT-2, a non
cancerous cell line, was prepared to investigate the effect of
weak expression of PSMA in a normal prostate cancer cell
line. Each cell was cultured in conditions of RPMI-1640
(Hyclone) supplemented with 10% FBS, 100 UmL1 Pennisylin
G, and 100 mg mL1 streptomycin at 37 1C in 5% CO2 humid
incubator. The cultured cells were trypsinized before preparing
a suspension state in serum free media. The cell numbers were
then counted, and 1  102, 1  103, and 1  104 cells in 400 mL
RPMI-1640 medium were used in EIS analysis.
As LNCaP (dashed white column in Fig. 3) or PC3
(horizontal lined gray column) cells increased to 1  102,
1  103 and 1  104 in aptamer-modified electrode immersed
solution (400 mL), Rct coincidentally increased, which indicates
a direct interaction between cells and the specific aptamers on
the working electrode. For both LNCaP and PC3 cells, this
sensor successfully detected to 1  102 cells irrespective of
PSMA-expression. However, Rct values were not changed by
sequential increments of non-prostate cancer cells, HeLa,
SW620, and MCF-7. On the other hand, weak increases of
Rct were shown for the PNT2 (black column) cell line,
indicating that PNT2 expresses PSMA in a small quantity.11
Binding of prostate cancer cells was indirectly confirmed by
physically detaching the cells from the electrode. Micrographs
and the cell numbers for the detached cells are presented in
Fig. S3.w It provides exact evidence for binding of prostate
cancer cells on the dual-aptamer conjugate modified gold
electrode.
In addition, we examined the specific detection of prostate
cancer cells when PNT2 was co-incubated as a background
material (Fig. 4). Since the PSMA is also expressed in the
PNT2 cell line, discriminative detection of prostate cancer cells
is required for practical application as a sensor. Resuspended
LNCaP and PC3 cells (1  102, 1  103, 1  104, and 1  105)
Fig. 2 Nyquist plots for each immobilization step: SAM layer
modification on the Au working electrode with biotin-thiol and
spacer-thiol (’), streptavidin immobilization step (J), dual-aptamer,
the A10 RNA aptamer and the DUP-1 peptide aptamer application
step (&), BSA-treatment step (m), and 1  102 prostate cancer cells
(PC3) binding step (K) (Inset: Plot for Rct values of each step).
Detailed conditions for EIS analysis are in the electronic supple-
mentary information.w
Fig. 3 A plot of Rct values of the Nyquist plot for the detection of
different numbers of the six cell types: HeLa, SW620, MCF-7, PNT2,
LNCaP, and PC3.
Fig. 4 Rct values of the Nyquist plot for extra added cells, PNT2 (’),
LNCaP (K), and PC3 (n), in 1  104 PNT2 cells contained in sample
solutions with different numbers: 0, 1  102, 1  103, 1  104, and
1  105 cells.
































































were additionally supplemented in a high concentration of
PNT2 normal cells (1  104) in 400 mL RPMI 1640 medium.
When different numbers of LNCaP and PC3 cells were
incubated with the electrode, the Rct values significantly
increased with both LNCaP cells and PC3 cells, even though
a high concentration of PNT2 cells was present in cell suspen-
sions. However, Rct values were slightly increased with
negligible change when only PNT2 cells were additionally
applied, in comparison to those of prostate cancer cells.
Distinction of Rct values between prostate cancer and normal
cells was clearly shown even if 102 cells of either LNCaP or
PC3 were present in 104 normal cells (Fig. 4). This suggests
that this dual-aptamer impedance sensor can be used for the
sensitive diagnosis of prostate cancer even if a small amount of
prostate cancer cells (B1%) exists among a great quantity of
normal cells such as in surgically removed suspicious prostate
tissues for a biopsy test. The biopsies can be prepared
with ease of patients’ pain because only a really small amount
of cells is needed for this diagnosis method based on its
sensitivity. It can provide accurate results from more biopsy
specimens from a patient.
In this study, we synchronously detected both prostate cancer
cells, PSMA (+) and PSMA () cell lines, with a high specificity
using a single dual-aptamer conjugate system by means of EIS.
This cell-based, direct, and sensitive method can be widely
applied for preliminary diagnosis. In addition, these sensitive
electrochemical approaches with the smart dual-aptamer probe
can be expected to be recognized as a non-painful biopsy test.
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